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Highlights 
 The potential of CDs in the CE resolution of drug enantiomers is described 
 Enantioseparation mechanisms for chiral drugs in CE with CDs are studied 
 Applications of the developed chiral analytical CE methods using CDs are presented 
Applications of CE with CDs to the chiral analysis of drugs: quantitative analysis, 
enantiomeric purity, stability studies, biological samples, metabolism studies, 






The most recent advances on the use of cyclodextrins as chiral selectors in capillary 
electrophoresis for the enantioseparation of drugs are reviewed in this article. The types of 
cyclodextrins employed and the resolutions achieved are discussed. The use of dual chiral 
systems, modified capillaries, non-aqueous media or microfluidic devices is also included and 
the mechanisms for enantioseparation of drugs and the inversion of the enantiomer migration 
order are studied. The most relevant applications developed to carry out the quantitation of 
chiral drugs, to assess the enantiomeric purity of pharmaceutical formulations, to study their 
metabolism or to achieve criminalistic or forensic investigations are described. Articles 
published in the last six years (period from 2010 to 2015) are considered. 
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1. Introduction 
The determination of the enantiomers of chiral drugs is of crucial importance in pharmaceutical 
analysis since one of the enantiomers can be active from a pharmacological point of view, while 




increasing use of drugs marketed as pure enantiomers requires the control of the enantiomeric 
impurities using potent and sensitive analytical techniques. 
Capillary Electrophoresis (CE) is a powerful technique for chiral analysis [1-4]. Among the 
advantages of CE, its simplicity, high efficiency, versatility, rapid analysis, high-resolution power, 
small sample volume required and low operating costs can be cited. Moreover, coupling of CE 
with mass spectrometry detection confers to CE a high sensitivity together with the possibility 
of unequivocal identification of drugs or their impurities or metabolites in a variety of complex 
matrices such as pharmaceutical formulations or biological samples.  
Most chiral separations by CE are carried out by adding a chiral selector to the separation buffer 
[5]. The chiral selector forms a complex with both enantiomers, giving rise to differences in the 
electrophoretic mobility between them. Cyclodextrins (CDs), crown ethers, proteins, 
surfactants, macrocyclic antibiotics, ligand-exchange complexes and polysaccharides are 
important types of chiral selectors used in chiral CE. Among all types of chiral selectors described 
in the literature, CDs are the most frequently employed [6]. 
CDs are cyclic oligosaccarides that consist of (α-1,4)-linked α-D-glucopyranose units. α-, β- and 
γ-CDs contain six, seven and eight glucose units, respectively, and form a ring with a truncated 
cone shape. CDs form inclusion complexes with the enantiomers whose stability depends on the 
molecular properties of the enantiomer and the CD. The variety in the diameter of the cavity 
and the substituents in the CD provide the possibility of enantioseparations of many chiral 
compounds with different size and functional groups using uncharged, positively and negatively 
charged CD derivatives [7, 8]. Moreover, the high solubility of CDs in aqueous media and their 
low UV absorbance are advantages to be employed in CE [9]. In fact, native and derivatized CDs 
have been used to achieve the enantioseparation of a wide variety of chiral drugs by CE.  
In this article, the main developments and applications of chiral CE with CDs in pharmaceutical 
analysis that have taken place during the last six years are reviewed. Articles published in the 
period of time from 2010 to 2015 have been considered. In the course of these years, some 
review articles dealing with specific subjects of the use of chiral CE in pharmaceutical analysis 
have been published. In particular, the enantioseparation of drugs with multiple chiral centers 
[10], the use of non-aqueous capillary electrophoresis (NACE) [11], the application of antibiotics 
as chiral selectors [12, 13], and the enantioseparation of fluoroquinolones drugs [14] have been 
reviewed.  
2. Types of CDs used in the enantioseparation of drugs 
Table 1 shows the types of CDs employed to achieve the enantiomeric separation of compounds 
of pharmacological interest. In general terms, the best enantiomeric separations were obtained 
with anionic CDs [15-26] probably because the anionic CD derivatives migrate toward the anode 
against the EOF which increases the migration time giving rise to more opportunities to the 
interaction between the analyte and the CD improving the enantioresolution. The 
enantioseparation of positively charged basic drugs is further improved with anionic CD 
derivatives due to: i) the opposite charge which increases the affinity between the enantiomers 
and the CD, and ii) the opposite electrophoretic mobility of the enantiomers and the CD. 
Nevertheless, sometimes neutral CDs gave better separations than anionic ones [27-31]. It can 
be observed in Table 1 that anionic β-CD derivatives have been the most commonly used CDs 
for the enantioseparation of drugs, probably because the size of their cavity fits better to the 
size of the majority of drugs. Nevertheless, the cavity may not fit the size of the drug but rather 




The resolution (Rs) values obtained for the compounds separated with each CD employed in the 
reviewed period are also grouped in Table 1. When the numerical values of Rs are not given in 
the original article, it is indicated in the table if the enantiomeric separation was possible (R) or 
not (NR). It can be observed that β-CD, carboxymethyl-β-CD (CM-β-CD), hydroxypropyl-β-CD 
(HP-β-CD), highly sulfated-γ-CD (HS-γ-CD) and sulfated-β-CD (S-β-CD) were the most employed 
CDs for the enantiomeric separation of chiral drugs by CE. In order to compare the results 
obtained with neutral and anionic β-CDs, Table 2 shows the best enantioresolution achieved for 
a group of drugs with both types of CDs. For some compounds such as 1-(4-methoxyphenyl)-2-
(methylamine)-ethanol, 2-amino-1-phenyl-ethanol, atenolol, butylone, cetirizine, chloroquine, 
mefloquine, mephedrone, methoxytolterodine, metoprolol, naphyrone, ofloxacin, ornidazole, 
primaquine, promethazine, quinacrine, salbutamol and tolterodine, a higher resolution was 
achieved using anionic β-CDs. Nevertheless, for amlodipine, carvedilol, quinocide, sibutramine, 
sotalol and tafenoquine the resolution was better when neutral β-CDs were employed. 
As it is known, the chiral separation of drugs with CDs could be improved by optimizing the CD 
concentration [17, 19-21, 23, 24, 31-41], the BGE pH [15, 20, 21, 24, 25, 27, 28, 33-35, 38, 39], 
the buffer co-ion [18-21, 23, 24, 28], by adding organic solvents (e.g., acetonitrile, methanol, 
ethanol, isopropanol) [17] [28] [24] [31] [38] [42-44] or other additives such as cations (e.g., 
guanidine) [45], surfactans (e.g., SDS) [43] and PEG 4000 [46]. Many articles have shown an 
increase in the enantiomeric resolution when increasing the CD concentration [17, 32, 35, 38, 
etc]. This can be justified by the higher number of interactions that may occur between analytes 
and the CD. Moreover, when increasing the CD concentration, the viscosity of the BGE increases 
and the EOF decreases, giving rise to longer migration times generating further opportunities 
for interactions between the analyte and the CD molecules. However, various studies also 
showed that when the CD concentration is continuously increased, a maximum value for the 
enantioresolution is reached depending the optimum CD concentration on the binding affinity 
of the analyte and the CD [19, 36, etc]. When the concentration of the CD is raised over an 
optimum value, the resolution can decrease due to the fact that all analyte molecules are 
complexed and the separation depends on the differences in the electrophoretic molibities of 
both enantiomer-CD complexes which are very similar. Furthermore, the decrease in the EOF 
due to the increase in the viscosity of the BGE originates longer migration times, leading to peak 
width broadening and decreasing further the resolution [24, 33, 39, 40].  
An inversion in the migration order of the enantiomers may be observed when increasing the 
CD concentration. This was the case of the separation of sibutramine enantiomers with β-CD 
and acetyl-β-CD (A-β-CD) (Figure 1) [41] or of tolterodine and methoxytolterodine enantiomers 
with S-α-CD and S-β-CD [23]. This phenomenon can be justified taking into account that when 
the CD concentration is sufficiently high, most of the analyte molecules exist as CD complexes 
and the migration is determined by the electrophoretic mobility of the inclusion complexes and 
not by the affinity of enantiomers to the CD. As a consequence, a reversal in the migration order 
may be produced [1, 47-51]. 
When a non-satisfactory enantioseparation was obtained using a single CD system, dual chiral 
systems consisting of two different CDs [25, 52-56] or a CD plus a chiral ionic liquid (IL) [57-60], 
a chiral antibiotic [61], a polysaccharide [62] or a crown ether [63] were investigated in order to 
improve the chiral resolution (see Table 3). A mixture of two different CDs may increase the 
enantioseparation based on the differences in the complexation mechanisms of the two CDs 
with the enantiomers. In this regard, various dual CD systems were studied in the separation of 




antagonist melatoninergic ligands. Good results were obtained with HS-β-CD + α-CD, HS-β-CD + 
γ-CD, HS-β-CD + HP-α-CD and HS-α-CD + HP-γ-CD [53]. In order to enhance the enantioresolution 
of meptazinol intermediate III and intermediate IV, dual CD systems of mono-6-deoxy-6-
piperidine-β-cyclodextrin in combination with three different neutral CDs (β-CD, trimethyl-β-CD 
(TM-β-CD) and HP-β-CD) were tested [54]. The dual CD system consisting of mono-6-deoxy-6-
piperdine-β-CD and HP-β-CD was shown to be the most efficient to enhance the simultaneous 
enantioresolution of both intermediates (Figure 2). Mixtures of CDs and ionic liquids (IL) have 
also shown a high potencial to enhance enantiomeric separations. It has been demonstrated, 
for example, the synergistic effect of the ionic liquid (1-ethyl-3-methylimidazolium-L-lactate) 
plus a CD (HP-β-CD or β-CD) in the enantioseparation of a large number of chiral drugs (Figure 
3) [57, 58]. 
The migration times of analytes can frequently shift with uncoated capillaries due to the 
difficulty in controlling EOF. Internal standards may be used to correct such shifts. Another 
approach is to modify the internal capillary wall with an appropriate reagent. In this regard, a 
new type of chemically modified capillaries having diol groups was developed and applied to the 
chiral analysis of methamphetamine and related compounds by CE with CDs (β-CD and dimethyl-
β-CD (DM-β-CD)). The migration time of each enantiomer in urine of methamphetamine addicts 
was the same as each enantiomer had in a standard solution. Thus, it was possible to identify 
enantiomers without any correction. On the other hand, with untreated fused-silica capillaries, 
the shifts of migration times of these enantiomers were too large to allow identification [56]. 
The repeatability and chiral resolution achieved with four types of chemically modified 
capillaries (FunCap-CE/Type D (possessing diol groups), Type A (amino groups), Type C (carboxyl 
groups), and Type S (sulfate groups)) which were used for the CE separation of 
methamphetamine enantiomers with S-γ-CD were evaluated. The best results were obtained 
with type S capillaries [64]. In a later study, Type S capillaries were employed to carry out the 
simultaneous chiral separation of 8 amphetamine-type stimulants (amphetamine, 
methamphetamine, norephedrine, norpseudoephedrine, ephedrine, pseudoephedrine, 
dimethylamphetamine and methylephedrine) with S-γ-CD by CE/MS/MS. A good repeatability 
of migration times and a high identification power of analytes were obtained due to the use of 
the MS/MS detection system [65].  
Non-aqueous BGEs in CE (NACE) have not extensively been used in the enantioseparation of 
drugs with CDs in this period. The main advantages of NACE to achieve the enantiomeric analysis 
of drugs are the ability to dissolve hydrophobic analytes, lower conductivity, compatibility with 
mass spectrometric detection, feasibility of ion-pair formation, etc. Moreover, organic solvents 
possess lower dielectric constants than water, and intermolecular interactions between de CD 
and the analyte are promoted favouring the chiral discrimination. There are various articles in 
which aqueous and non-aqueous media are compared in the separation of chiral drugs [66-68]. 
Significant differences were found between the separation mechanisms in both media. For 
example, the enantiomers of propranolol formed inclusion complexes with HDMS-β-CD in 
aqueous BGEs and external type complexes in methanolic BGEs, and the opposite was true with 
HDAS-β-CD [66]. 
Microfluidic chip-CE devices were developed and applied to the chiral analysis of drugs. The 
simultaneous enantioseparation and determination of anisodamine (AN), atenolol (AT), and 
metoprolol (ME) in human urine was carried out using CM-β-CD as chiral selector (see Figure 4). 
The microfluidic-CE device developed incorporated on-chip dilution to facilitate the large 




(ECL) detection was used to improve detection sensitivity. The methodology developed allowed 
to obtain important information for the treatment of stroke patients [69]. 
3. Enantioseparation mechanisms in CE with cyclodextrins 
The separation mechanism of enantiomers in CE using CDs as chiral selectors is usually based on 
the formation of inclusion complexes where the enantiomer analyte fits into the CD cavity. The 
cavity size of the CD and the shape and structure of the analyte are important factors for chiral 
recognition. Furthermore, interactions between functional groups of the analyte and the 
hydroxyl groups on the CD-rim are also responsible for the chiral recognition and separation.  
The characterization of interactions of enantiomers with CDs is a helpful tool in chiral CE 
research for a better understanding of the separation mechanism and the prediction of 
migration behaviour. Generally, the difference between the electrophoretic mobility for both 
enantiomer-CD complexes is negligible, and the separation is determined by their different 
stability constants. The stability constants and the electrophoretic mobilities of inclusion 
complexes of sibutramine enantiomers with methyl-β-CD (M-β-CD) were determined. The 
stability constant was higher for the (R)-enantiomer than for the (S)-enantiomer. However, the 
electrophoretic mobilities of both sibutramine enantiomer complexes were the same. 
Therefore, the separation of sibutramine enantiomers was mainly due to the different stability 
constants of the inclusion complexes [18].  
Rarely, there is an inversion of the enantiomer migration order when the chiral selector 
concentration is increased. At low β-CD and A-β-CD concentrations, (S)-sibutramine migrated 
faster than (R)-sibutramine. However, at higher CD concentrations, (R)-sibutramine migrated 
faster than (S)-sibutramine. To explain this phenomenon, the binding constants and the 
electrophoretic mobilities of the inclusion complexes of sibutramine β-CD and sibutramine A-β-
CD complexes were determined. At low β-CD and A-β-CD concentrations, the migration order 
was determined primarily by the stability of the complexes since most of the enantiomer 
molecules in solution are unbound. At higher β-CD and A-β-CD concentrations, most of the 
enantiomer molecules existed as CD complexes and the migration order was determined by the 
electrophoretic mobility of the complexes [41].  
An alternative to the conventional direct technique to determine stability constants is the use 
of partial (PFT) and complete (CFT) filling techniques in which the capillary is partially or totally, 
respectively, filled with the chiral selector solution prior to the injection of the analyte, while the 
BGE remains without chiral reagent. Using CFT may ensure that enantiomers do not exit to the 
CD plug during the electrophoretic separation, simplifying the calculations. In this regard, a CFT 
technique was used to determine the stability constants of enantiomer-CD complexes of four 
antihistamines (dimethindene, promethazine, orphenadrine and terfenadine) and four 
antidepressants (bupropion, fluoxetine, nomifensine and viloxazine) drugs with HS-β-CD [70]. 
Nuclear magnetic resonance (NMR) has extensively been employed to know the structure of the 
inclusion complexes formed between the enantiomers of chiral drugs and CDs to explain the 
molecular mechanism underlying the behaviour observed in chiral CE. Structural differences 
were observed by using monodimensional rotating frame nuclear Overhauser effect 
spectroscopy (1D ROESY) between the complexes of propranolol with native β-CD and HS-β-CD 
in aqueous BGEs, which can explain the migration order of propranolol enantiomers using these 
two CDs as chiral selectors [71]. The structure of complexes formed between propranolol 
enantiomers and HDMS-β-CD and HDAS-β-CD in aqueous and non-aqueous media were 




propranolol form inclusion type complexes with HDMS-β-CD in an aqueous BGE but external 
type complexes in a methanolic BGE, and the opposite was true for HDAS-β-CD [66]. 
Enantioselective ROESY experiments indicated that S-propranolol formed a tighter complex with 
HDAS-β-CD than R-propranolol [72]. 1D ROESY experiments showed a deeper inclusion of the 
aromatic moiety of the molecule of ephedrine enantiomers into the cavity of β-CD compared to 
α-CD, and this result suggests a stronger interaction between ephedrine and β-CD than between 
ephedrine and α-CD which is in good accordance with CE experiments [73]. The mechanism of 
chiral recognition between norephedrine (NEP) enantiomers with various CDs (α-CD, β-CD, 
HDMS-β-CD and HDAS-β-CD) in chiral CE was studied by 1H-NMR and 1D ROESY spectroscopy. 
Structures of analyte-CD complexes were proposed (Figure 5) [74]. The structure of the inclusion 
complexes of sibutramine enantiomers with M-β-CD was investigated by 1H-NMR and 2D ROESY 
spectroscopy. Not only the aromatic moiety but also methyl groups were included into the inner 
cavity of M-β-CD. The aromatic moiety would be positioned close to the narrow rim of M-β-CD 
and the methyl chain would be positioned near the large rim [75]. The effect of the cavity size 
of various CD derivatives (TM-α-CD, TM-β-CD and TM-γ-CD) on the separation of Ketoprofen 
enantiomers by chiral CE was studied by NMR. With TM-α-CD and TM-β-CD the (R)-enantiomer 
migrated first, whereas with TM-γ-CD the opposite happened. Based on NMR experiments 
different structures were proposed for each analyte-CD complex to explain the different affinity 
pattern of ketoprofen enantiomers toward these chiral selectors [76]. NMR experiments 
indicated that HP-β-CD formed a more stable complex with (R)-duloxetine than with (S)-
duloxetine, and (S)-duloxetine bind to M-γ-CD more strongly than (R)-duloxetine. But 
enantiomer migration order obtained in CE experiments was not in agreement with these data. 
Therefore, enantioseparation may be determined by electrophoretic mobilities of inclusion 
complexes [77].  
Molecular modelling techniques contribute to understand the enantioseparation mechanism 
and to predict the elution of enantiomers. Using molecular modelling techniques, optimized 
geometries for the lowest energy conformation for the inclusion complexes of ornidazole and 
ofloxacin enantiomers with S-β-CD were obtained. The stability of proposed geometries 
explained the different migration times observed in experimental studies [15]. Based on 
molecular simulation and theoretical calculations using computer-aided techniques, the order 
of elution of bupivacaine enantiomers in chiral CE with sulfobutyl ether β-CD (SBE-β-CD) was 
determined. The conformational energy of the complex formed by (S)-bupivacaine and SBE-β-
CD was smaller than that of the complex between (R)-bupivacaine and SBE-β-CD [20]. Molecular 
modelling studies may significantly contribute to understand the nature of the intermolecular 
forces responsible for analyte–CD interactions and chiral recognition when they are used in 
combination with instrumental techniques, especially with ROESY experiments in NMR 
spectroscopy. A combination of molecular modelling and NMR was used to study the separation 
mechanism of enantiomers of the basic drugs bupivacaine and propranolol with the anionic CD 
derivatives HDMS-β-CD and HDAS-β-CD with NACE. For bupivacaine, 2D ROESY experiments 
showed that inclusion complexes were not formed, and the interaction of bupivacaine with CDs 
should involve the sulfate groups of the CD derivatives. In the case of propranolol, NMR 
experiments suggested that external complexes were formed between propranolol 
enantiomers and HDMS-β-CD while in the presence of HDAS-β-CD the alkyl chain of (R)-
propranolol was assumed to enter into the CD cavity through the wider opening. The most 
energetically favourable geometries of the complexes between bupivacaine and propranolol 
enantiomers and both CD derivatives were determined by molecular modelling techniques and 




docking and binding energy calculations between iodiconazole enantiomers and structurally 
related analogues with HP-γ-CD were carried out. Iodiconazole enantiomers were inserted into 
the hydrophobic cavity of HP-γ-CD. 2D NMR spectroscopy confirmed that conclusion. The 
mathematical equation proposed to calculate the enantiomeric resolution demonstrated good 
capability to predict the experimental chiral separation of these compounds in CE with HP-γ-CD 
[79]. A combination of isothermal titration calorimetry (ITC), NMR and molecular modelling 
techniques was used to provide a deeper understanding of the chiral recognition processes 
between β-CD or CM-β-CD and four chiral drugs (2-amino-1-phenyl-ethanol, 1-(4-
methoxyphenyl)-2-(methylamine) ethanol, salbutamol sulfate and sotalol hydrochloride). When 
native β-CD was employed, no enantioseparation was obtained, but the enantioseparation was 
significantly improved with CM-β-CD. The ITC results showed that the high enantioseparation 
efficiency of CM-β-CD was associated with a strong binding affinity between drug molecules and 
chiral selector. However, the behaviour of salbutamol sulfate was an exception to this rule 
suggesting that the binding strength alone was not enough to explain the enantioseparation 
behaviour. The inclusion geometry obtained by autodock simulation was in agreement with the 
NMR experiments, and the calculated binding energies were also in agreement with the 
association constants obtained by ITC and with the CE enantioseparation results. Experimental 
results indicated that electrostatic interactions and hydrogen bonds play an important role in 
the enantiorecognition of these drugs with CM-β-CD [26]. Molecular modelling techniques have 
also been used in combination with MS for investigations of the enantiorecognition mechanism 
between drug enantiomers and CDs. A 1:1 stoichiometry for the inclusion complexes of ofloxacin 
enantiomers with HP-β-CD was obtained from MS studies. Quantum mechanics calculations of 
the binding energies for both enantiomers with the CD were in good accordance with the 
migration orders obtained in the CE experiments. And the most likely conformations for both 
enantiomer-CD complexes were generated by molecular mechanic calculations [60]. 
When a CD + IL dual chiral system was employed, as in the case of the CE enantioseparation of 
various chiral drugs by using HP-β-CD and the ionic liquid 1-ethyl-3-methylimidazolium-L-lactate 
([EMIm][L-lactate]) in the BGE, the separation mechanism may be explained by the formation of 
an inclusion complex between enantiomers and CD, and the association of enantiomers with 
the IL either coated onto the inner capillary wall or free in the BGE.  It has also been 
demonstrated that increasing the chain length of the cationic part of IL, the CE 
enantioseparation improved. Shorter alkyl chains (1-ethyl-3-methylimidazolium) are less 
hydrophobic than longer ones (1-butyl-3-methylimidazolium or 1-heptyl-3-methylimidazolium) 
and they formed a less stable bilayer inside the capillary, whereas a stable bilayer inside the 
capillary might allow a more stable environment for the separation of analytes. On the other 
hand, the nature of the anionic part of IL (L-lactate or Br) had little influence on the 
enantioseparation [57, 58]. 
4. Quantitative analysis 
Chiral CE with UV detection was applied to quantitate drugs enantiomers. Table 4 summarizes 
the LODs obtained in the quantitative determinations. Some of the quantitative methods 
developed were applied to determine the enantiomers of the active ingredient in commercial 
formulations. The amount of sibutramine enantiomers was determined in two commercial 
formulations by using chiral CE with M-β-CD. There was no significant difference between values 
obtained and labelled amounts [18]. The enantiomers of ofloxacin and ornidazole using S-β-CD 
as chiral selector were determined simultaneously in tablets. A good agreement with the value 




enantiomers of iodiconazole separated with chiral CE using HP-γ-CD, the LOD was 4.6 µg/mL 
[33]. A quantitative chiral CE method using CM-β-CD enabled the separation of meptazinol 
enantiomers with a LOD of 2.50 µg/mL. The method was applied to determine meptazinol in 
tablets [24]. Quantitation of sotalol enantiomers by chiral CE was carried out using the RAMEB. 
The LODs were 1.13 µg/mL for (R)-sotalol and 1.25 for (S)-sotalol. The method was suitable for 
the determination of sotalol in tablets [31]. The determination of amlodipine enantiomers using 
RAMEB as chiral selector in the BGE was achieved, being the LODs 2.31 µg/mL for the (R)-
enantiomer and 2.43 µg/mL for the (S)-enantiomer. The method was applied to the 
enantiomeric determination of amlodipine tablets. The result was in good agreement with that 
declared by the manufacturers [27]. Moreover, the determination of carvedilol enantiomers was 
carried out using β-CD as chiral selector. The LODs were 1.13 µg/mL for the (R)-enantiomer and 
1.18 µg/mL for the (S)-enantiomer. The method was applied to the analysis of tablets [28]. The 
enantiomeric quantitation of sibutramine was carried out by developing a method based on the 
use of M-β-CD. The LOD was 0.25 µg/mL and a 0.05% of (S)-enantiomer can be detected in a 
mixture of both enantiomers [75]. 
Several methods were applied to degradation studies of formulations. The use of SBE-β-CD 
enabled the quantitation of isradipine enantiomers in a pharmaceutical formulation. The LODs 
were 2.16 - 3.68 µg/mL. The method was also applied to the determination of isradipine 
enantiomers in degradation studies. The drug was subjected to oxidation, hydrolysis and 
photolysis. Isradipine enantiomers were separated from their degradation products and 
formulation excipients [32]. A CE enantioselective method with CM-β-CD was developed for the 
simultaneous quantitation of zopiclone enantiomers and its impurities in tablets. The method 
was applied to determine the degradation and racemization of zopiclone under stress conditions 
(acid and alkaline hydrolysis studies, oxidative studies and photo degradation studies). LODs for 
impurities were from 0.01 to 0.02 µg/mL [80].  
Other quantitative methods were applied to the determination of the enantiomeric purity of 
pharmaceutical formulations. Thus, a stereoselective CE assay was developed for the 
determination of the enantiomeric purity of chloroquine using SBE-β-CD as chiral selector. The 
LOD was 0.6 µg/mL for both enantiomers. The method was applied to analyze the enantiomeric 
purity of synthetic samples. A 0.24% of (S)-enantiomer can be detected in a mixture of both 
enantiomers [81]. When using S-β-CD, the LOD for the (S)-cetirizine enantiomer was 0.075 
µg/mL. The developed method allowed to determine at least 0.1% (w/w) of the (S)-cetirizine 
impurity. The method was applied to the enantiomeric purity control of (R)-cetirizine 
dihydrochloride tablets [35]. The (R)-enantiomer of ornidazole is an enantiomeric impurity in 
starting materials and pharmaceutical formulations of levornidazole. A chiral CE method with S-
α-CD was developed to determine levornidazole and its enantiomeric impurity in levornidazole 
injection solutions. The LOD was 0.3 µg/mL (0.006%) [21]. Also, the determination of the optical 
impurity (S)-tolterodine by chiral CE with P-γ-CD was achieved. The LOD was 0.33 µg/mL. The 
proposed method was capable of determining 0.2% of (S)-tolterodine in pills [23]. In addition, 
the determination of the enantiomeric impurity of (R)-amlodipine at the 0.2 % level was carried 
out by CE using CM-β-CD. The LOD was 1.0 µg/mL. The method was applied to determine the 
enantiomeric purity of levamlodipine in bulk samples [39]. Chiral CE was also successfully 
applied to the enantiomeric purity determination of valsartan using A-β-CD into the BGE. The 
LOD for the (R)-enantiomer impurity was 0.01 %. The assay was applied to commercial products 
[34]. On the other hand, a dual system was employed enabling the quantitation of ofloxacin 
enantiomers using HP-β-CD and the ionic liquid 1-ethyl-3-methylimidazolium-L-lactate. The LOD 




ofloxacin in bulk samples of (S)-ofloxacin. The amount of the chiral impurity was well below 0.2% 
[57]. Also, the chiral purity of eszopiclone in commercial tablets was determined by using a CD-
IL dual system (β-CD and 1-ethyl-3-methylimidazolium-L-lactate). The concentration of the chiral 
impurity (R)-zopiclone was < 0.1% and the LOD value for the impurity (R)-zopiclone was found 
to be 0.3 µg/mL [58]. 
5. Sensitive analytical methodologies  
Sensitive analytical methodologies are especially required when biological fluids are analyzed. 
Alternative detection systems to UV detection and preconcentration methods have been 
applied in chiral CE in order to obtain the necessary sensitivity [82, 83].  
Regarding detection sensitivity, it is a critical point in CE when low LOD is required. The 
concentration sensitivity obtained in CE with UV detection is usually low due to the short optical 
path length (50–100 µm). To improve the LOD, detection systems of higher sensitivity than UV 
detection have been employed. Thus, bupropion enantiomers were resolved and quantitated in 
a pharmaceutical formulation and in a spiked urine sample by CE using S-α-CD as chiral selector. 
A sensitized time-resolved phosphorescence detection mode was used. The LOD obtained for 
each enantiomer was 2x10-7 M (0.048 µg/mL), which means an improvement of the sensitivity 
by a factor of more than 10 over that achieved with UV detection. A home-built detection system 
was used. The excitation energy from a pulsed laser at 266 nm is transferred from the analyte 
to an acceptor (1-bromo-4-naphthalenesulfonic acid) followed by time-resolved 
phosphorescence detection. Time resolution avoids light scattering problems and fluorescence 
due to impurities into the sample, since the lifetime of phosphorescence is larger than 
fluorescence. The sensitized phosphorescence mode is particularly well suited for analytes with 
poor phosphorescence. In this mode, the analyte acts as an energy donor to a phosphorescent 
acceptor [84]. 
Conductivity detection enables to analyze non-UV-absorbing compounds with good sensitivity 
without chemical derivatization. A quantitative method was developed for the analysis of 
bupivacaine using conductivity detection. The method was applied in rabbit serum and 
pharmaceutical injections. The LODs were 0.26 µg/mL and 0.052 µg/mL, respectively probably 
due to worse S/N ratio in the serum samples. Compared with UV detection, conductivity 
detection has a clear advantage in trace analysis [20]. 
Anisodamine, atenolol, and metoprolol enantiomers were separated and quantitated in spiked 
human urine by using a microfluidic chip-CE device and CM-β-CD as chiral selector and 
electrochemiluminescence detection. LODs were in the range 0.3-0.6 µM (0.08-0.18 µg/mL) 
[69]. 
A CE-ESI-MS/MS assay using succinyl-γ-CD (Succ-γ-CD) was developed and applied to the 
determination of L- and D-carnitine in pharmaceutical formulations (ampoules, oral solutions, 
sachets, and tablets). The LOD for both enantiomers was of 0.010 μg/mL allowing to detect a 
0.002% of the D-enantiomer impurity with respect to the main L-enantiomer [85]. UV and TOF-
MS detection were compared in the separation of 12 cathinone analogues. The MS detector 
provided lower LODs for nine out of 12 analytes [38]. The enantiomeric purity of duloxetine was 
determined by chiral CE with HP-β-CD and UV detection at 220 nm, and with MS detection. The 
LODs were 0.2 µg/mL by CE-UV and 0.02 µg/mL by CE-MS, enabling to detect 0.02% of 
enantiomeric impurity [86]. To avoid the suppression effect of the MS signal by CDs, the partial 
filling technique of the capillary is commonly used, but resolution may be negatively affected. In 
this regard, low-flow nano-ESI was applied to the CE enantioseparation and detection of 




enantioresolution was obtained due to the presence of the HS-γ-CD into the entire capillary 
during the analysis [63]. 
With respect to preconcentration methods, electromembrane extraction (EME) and dispersive 
liquid–liquid microextraction (DLLME) were employed to improve LODs in the analysis of chiral 
drugs by CE. 
In EME methods, ionized analytes are extracted from sample solutions through a supported 
liquid membrane (SLM) on a porous hollow fiber, into an acceptor solution located inside the 
lumen of the hollow fiber by applying an electrical field across the wall (Figure 6). An EME 
preconcentration method was developed for the determination of trimipramine in plasma and 
urine samples. The extract was analyzed by using CE with α-CD. The LOD for both enantiomers 
was 7 ng/mL [36]. Amlodipine enantiomers were extracted from plasma and urine samples using 
and EME method with a supported liquid membrane consisting of 2-nitrophenyl octyl ether 
impregnated on the wall of a hollow fiber. The enrichment factor obtained was about 124. The 
extract was analyzed by chiral CE using HP-α-CD, and the LOD for both enantiomers was 3-5 
ng/mL [87]. Enrichment factors in the range of 108-134 for propranolol enantiomers from urine 
and plasma samples were obtained using an EME method and CE with HP-β-CD (Figure 7). The 
LODs obtained for both enantiomers in urine and plasma samples were 7 and 10 ng/mL, 
respectively. 2-Nitro phenyl octylether was used as the supported liquid membrane. [37]. 
When a DLLME method is used, an extraction and a disperser solvent are mixed with the 
aqueous sample to form a cloudy solution. After the extraction of analytes is achieved, phases 
are separated by centrifugation. The extract is evaporated to dryness and the residue is 
reconstituted in a small volume for injection into the CE system. The chiral separation and 
determination of several illicit drugs (DL-methamphetamine, DL-3,4-
methylenedioxymethamphetamine and DL-ketamine) in prepared forensic samples (banknotes, 
kraft paper, plastic bag and silver paper) was made by using a DLLME method for sample 
preparation and a chiral CE system with β-CD and UV detection at 200 nm. The LODs were 
between 0.08 and 0.2 ng/mL [88]. The determination of hydroxyzine and cetirizine enantiomers 
in liquid culture media was achieved by using CE with S-β-CD as chiral selector and UV detection 
at 214 nm. The hydroxyzine and cetirizine enantiomers were extracted using a DLLME method. 
The LODs were 0.037 and 0.075 µg/mL, respectively, for cetirizine and hydroxyzine [22]. A 
DLLME preconcentration method was developed for the enantioselective analysis of zopiclone 
and its metabolite N-desmethylzopiclone by chiral CE using CM-β-CD and UV detection at 310 
nm after fungal biotransformation (Figure 8). The LODs for zopiclone and N-desmethylzopiclone 
were 0.27 and 0.15 ng/mL, respectively. The fungal biotransformation of zopiclone to N-
desmethylzopiclone was demonstrated to be enantioselective [25]. A DLLME method in 
combination with CE-field amplified sample injection (FASI) was developed for the chiral 
separation and determination of carvedilol in human plasma using CM-β-CD and UV detection 
at 241 nm. LODs for both enantiomers were 4 ng/mL [40].  
A FASI method was developed to improve the detection sensitivity of pindolol, oxprenolol and 
propranolol enantiomers separated by CE with a dual CD system (DM-β-CD + TM-β-CD) and 
achiral ionic liquids as modifiers. The LODs were between 0.11 and 0.26 ng/mL. The method was 
applied to the analysis of spiked urine samples [55]. 
6. Metabolism of drugs 
Chiral CE has shown a high potential to carry out metabolic studies of chiral drugs to investigate 




Ketamine is metabolized by the hepatic cytochrome P450 (CYP) enzyme system through N-
demethylation to norketamine followed by hydroxylation of norketamine. The stereoisomers of 
ketamine and its metabolites were analyzed by CE using S-β-CD to identify cytochrome P450 
enzymes involved in hepatic ketamine and norketamine biotransformation in vitro. Ketamine 
and norketamine enantiomers were incubated with different types of CYP enzymes. The data 
suggested that in vitro biotransformation of ketamine and norketamine is stereoselective [89]. 
Moreover, the CYP3A4-catalyzed N-demethylation kinetics of ketamine to norketamine and its 
inhibition by ketoconazole in vitro was investigated by CE using HS-β-CD and γ-CD as chiral 
selectors. Data obtained showed that CYP3A4-catalyzed N-demethylation is stereoselective, and 
the inhibition by ketoconazole is not stereoselective. CYP3A4 is an enzyme responsible for the 
metabolism of more than 50% of commonly prescribed drugs [90]. HS-γ-CD was used to study 
the stereoselectivity of the metabolism of ketamine to norketamine via CYP3A4. The separation 
capillary was used itself as a microreactor for the enzymatic transformation of ketamine to 
norketamine via CYP3A4, followed by the on-line chiral CE separation and determination of 
reaction products. Figure 9 shows the increase in the production of the (S)-norketamine 
enantiomer over the (R)-enantiomer [91]. The proposed method was subsequently improved 
with a simplification of the composition of the reaction mixture, the omission of the capillary 
cooling step used previously, prolongation of the total capillary length, increase of the HS-γ-CD 
concentration and other parameters such as the number and secuence of plugs of enzyme and 
reactant solutions and the pressure used to introduce the plugs. The LOD was 0.8 µM (0.18 
µg/mL) for both norketamine enantiomers [92]. An enantioselective CE assay using S-β-CD as 
chiral selector for the separation of ketamine and its metabolites was applied to the in vitro 
study of the enantioselectivity of the metabolism of ketamine in microsomes of different species 
(humans, horses and dogs). It was demonstrated that ketamine was metabolized 
enantioselectively in all three species. A LOD of 0.02 µg/mL for ketamine and norketamine was 
obtained [93]. The enantioselective distribution of ketamine and norketamine in equine brain 
and cerebrospinal fluid (CSF) was investigated by chiral CE with S-β-CD. After injection of racemic 
ketamine, all enantiomers of ketamine and norketamine were detected in CSF and brain. After 
injection of S-ketamine, only S-ketamine and S-norketamine were detected. The LOD was 8 
ng/mL for both ketamine and norketamine enantiomers. A Liquid-liquid pre-concentration 
method was used [94]. 
7. Criminalistic and forensic investigations 
As above mentioned, a chiral CE method with β-CD using a DLLME procedure for sample 
preconcentration was applied to the enantioseparation and determination of illicit drugs 
(heroin, DL-methamphetamine, DL-3, 4-methylenedioxymethamphetamine and DL-ketamine) 
in prepared forensic samples (banknotes, kraft paper, plastic bag and silver paper) [88].  
Chemically modified capillaries were applied to the enantiomeric analysis of methamphetamine 
and related compounds in urine samples of methamphetamine addicts using CE with β-CD and 
DM-β-CD [56] and to the analysis of amphetamine-type stimulants (amphetamine, 
methamphetamine, norephedrine, norpseudoephedrine, ephedrine, pseudoephedrine, 
dimethylamphetamine and methylephedrine) in forensic samples by CE/MS/MS using S-γ-CD 
[64, 65]. Moreover, methamphetamine profiling (methamphetamine, amphetamine, ephedrine, 
pseudoephedrine, norephedrine, and norpseudoephedrine) of different seizures was carried 
out by CE with HS-γ-CD [64] and the enantioseparation of 13 new amphetamine-like designer 
drugs was possible by CE using S-β-CD [42]. Also, the chiral CE separation of 12 cathinone 




and applied to examine seized drugs. Mass spectrometry is a valuable technique for the 
identification of individual analytes present in seized drugs [38]. 
Conclusions 
Proper selection of the type of CD to be used to achieve enantiomeric separations of chiral drugs 
by CE is paramount. The best separations were obtained with CDs that possess negatively 
charged substituents, because the electrophoretic mobility of these CDs has opposite direction 
to that of the EOF and the migration time of the analyte is increased. As a consequence, the 
interactions between the analyte and the CD also increase. Moreover, the fact that many drugs 
have basic character and are positively charged in solution at acidic pH and they have higher 
affinity for negatively charged CDs, increases the recognition capability between them. β-CDs 
are the most commonly used chiral selectors for these compounds. In some cases, synergistic 
effects were observed when CDs are used together with other chiral selectors in dual chiral 
systems.  
NMR studies and computational simulation techniques have been applied to establish the 
structure of analyte-CD complexes and the mechanism of recognition and enantioseparation by 
chiral CE. The value of the stability constant of the analyte-CD complex plays an important role 
to interpret the electrophoretic behavior and the order of elution of both enantiomers.  
Many applications of CE to the enantiomeric analysis of chiral drugs have been reported, such 
as the quantitative analysis of pharmaceutical formulations and their enantiomeric purity, the 
degradation studies of drugs, the analysis of drug enantiomers in biological samples and the 
study of their metabolism, as well as its application in criminalistics and forensic investigations 
of illegal drugs. Finally, the development of extraction and preconcentration methods (e.g., EME 
and DLLME) and the use of detection systems of high sensitivity (e.g, time-resolved 
phosphorescence, electrochemiluminescence, conductivity and MS) enabled to improve the 
LODs which increased the potential of the chiral CE methodologies. 
Conflicts of interest 
Authors declare that they have no conflict of interest 
 
Acknowledgments 
The authors thank the Ministry of Economy and Competitiveness (Spain) for research project 
CTQ2013-48740-P.  
References 
[1] B. Chankvetadze, Capillary Electrophoresis in Chiral Analysis, John Wiley & Sons, Chichester, 
1997. 
[2] A. Van Eeckhaut, Y. Michotte, Chiral Separations by Capillary Electrophoresis, CRC Press, 
EEUU, 2009. 
[3] C. García-Ruiz, M.L. Marina, Chiral analysis by capillary electrophoresis, in: M.L. Marina, A. 
Ríos, M. Valcárcel (Eds.), Analysis and detection by Capillary Electrophoresis, Elsevier, 




[4] E. Sánchez-López, M. Castro-Puyana, M. L. Marina, A. L. Crego, Chiral Separations by Capillary 
Electrophoresis, in: J. Anderson, A. Berthod, V. Pino, A. M. Stalcup (Eds), Analytical Separation 
Science, Vol. 2: Special Liquid Chromatography modes and capillary electromigration 
techniques. Part II: Capillary Electromigration Techniques, Wiley-VCH, EEUU, 2015, pp. 731-774. 
[5] A. Van Eeckhaut, Y. Michotte, Chiral separations by capillary electrophoresis: Recent 
developments and applications, Electrophoresis 27 (2006) 2880-2895. 
[6] G.K.E. Scriba, Cyclodextrins in capillary electrophoresis enantioseparations - Recent 
developments and applications, J. Sep. Sci. 31 (2008) 1991-2011. 
[7] P. Rezanka, K. Navratilova, M. Rezanka, V. Kral, D. Sykora, Application of cyclodextrins in 
chiral capillary electrophoresis, Electrophoresis 35 (2014) 2701-2721. 
[8] L. Escuder-Gilabert, Y. Martin-Biosca, M.J. Medina-Hernandez, S. Sagrado, Cyclodextrins in 
capillary electrophoresis: Recent developments and new trends, J. Chromatogr. A 1357 (2014) 
2-23. 
[9] Z. Juvancz, R.B. Kendrovics, R. Ivanyi, L. Szente, The role of cyclodextrins in chiral capillary 
electrophoresis, Electropohoresis 29 (2008) 1701-1712. 
[10] Z.A. Al-Othman, A. Al-Warthan, S.D. Alam, I. Ali, Enantio-separation of drugs with multiple 
chiral centers by chromatography and capillary electrophoresis, Biomed. Chromatogr. 28 (2014) 
1514-1524. 
[11] I. Ali, M.M. Sanagi, H.Y. Aboul-Enein, Advances in chiral separations by nonaqueous capillary 
electrophoresis in pharmaceutical and biomedical analysis, Electrophoresis 35 (2014) 926-936. 
[12] S. Dixit, J.H. Park, Application of antibiotics as chiral selectors for capillary electrophoretic 
enantioseparation of pharmaceuticals: a review, Biomed. Chromatogr. 28 (2014) 10-26. 
[13] A.F. Prokhorova, E.N. Shapovalova, O.A. Shpigun, Chiral analysis of pharmaceuticals by 
capillary electrophoresis using antibiotics as chiral selectors, J. Pharm. Biomed. Anal. 53 (2010) 
1170-1179. 
[14] A.A. Elbashir, B. Saad, H.Y. Aboul-Enein, Recent Developments of Enantioseparations for 
Fluoroquinolones Drugs Using Liquid Chromatography and Capillary Electrophoresis, Curr. 
Pharma. Anal. 6 (2010) 246-255. 
[15] K.M. Al Azzam, B. Saad, R. Adnan, H.Y. Aboul-Enein, Enantioselective analysis of ofloxacin 
and ornidazole in pharmaceutical formulations by capillary electrophoresis using single chiral 
selector and computational calculation of their inclusion complexes, Anal. Chim. Acta 674 (2010) 
249-255. 
[16] K. Nemeth, G. Tarkanyi, E. Varga, T. Imre, R. Mizsei, R. Ivanyi, J. Visy, J. Szeman, L. Jicsinszky, 
L. Szente, M. Simonyi, Enantiomeric separation of antimalarial drugs by capillary electrophoresis 
using neutral and negatively charged cyclodextrins, J. Pharm. Biomed. Anal. 54 (2011) 475- 481. 
[17] S. Mohr, S. Pilaj, M. G. Schmid, Chiral separation of cathinone derivatives used as 





[18] H. Zhu, E. Wu, J. Chen, C. Men, Y.S. Jang, W. Kang, J.K. Choi, W. Lee, J.S. Kang, 
Enantioseparation and Determination of Sibutramine in Pharmaceutical Formulations by 
Capillary Electrophoresis, Bull. Korean Chem. Soc. 31 (2010) 1496-1500. 
[19] J. Zhou, H.C. Yao, H. Shao, Y.H. Li, Z.Z. Zhang, Enantioseparation of beta-agonists with 
carboxymethyl-beta-cyclodextrin by CE, J. Liq. Chromatogr. R. T. 35 (2012) 50-58. 
[20] Y. Li, Y.J. Yu, P.Y. Zhu, G.L. Duan, Y. Li, F.Y. Song, Chiral separation of bupivacaine 
hydrochloride by capillary electrophoresis with high frequency conductivity detection and its 
application to rabbit serum and pharmaceutical injection, Pharmazie 67 (2012) 25-30. 
[21] X.L. Deng, Y.Z. Yuan, E. Adams, A. Van Schepdael, Development and validation of a sensitive 
enantiomeric separation method for new single enantiomer drug levornidazole by CD-capillary 
electrophoresis, Talanta 106 (2013) 186-191. 
[22] S.S. Fortes, T. Barth, N.A.J.C. Furtado, M.T. Pupo, C.M. de Gaitani, A.R.M. de Oliveira, 
Evaluation of dispersive liquid-liquid microextraction in the stereoselective determination of 
cetirizine following the fungal biotransformation of hydroxyzine and analysis by capillary 
electrophoresis, Talanta 116 (2013) 743-752. 
[23] P. Lehnert, A. Pribylka, V. Maier, J. Znaleziona, J. Sevcik, M. Dousa, Enantiomeric separation 
of R,S-tolterodine and R,S-methoxytolterodine with negatively charged cyclodextrins by 
capillary electrophoresis, J. Sep. Sci. 36 (2013) 1561-1567. 
[24] J. Yu, Z. Jiang, T.M. Sun, F.F. Ji, S.Y. Xu, L. Wei, X.J. Guo, Enantiomeric separation of 
meptazinol and its three intermediate enantiomers by capillary electrophoresis: quantitative 
analysis of meptazinol in pharmaceutical formulations, Biomed. Chromatogr. 28 (2014) 135-141. 
[25] N.C.P. de Albuquerque, C.M. de Gaitani, A.R.M. de Oliveira, A new and fast DLLME-CE 
method for the enantioselective analysis of zopiclone and its active metabolite after fungal 
biotransformation, J. Pharm. Biomed. Anal. 109 (2015) 192-201. 
[26] L.B. Li, X. Li, Q. Luo, T.Y. You, A comprehensive study of the enantioseparation of chiral drugs 
by cyclodextrin using capillary electrophoresis combined with theoretical approaches, Talanta 
142 (2015) 28-34. 
[27] G. Hancu, M. Budau, L.K. Kantor, A. Carje, Cyclodextrine Screening for the Chiral Separation 
of Amlodipine Enantiomers by Capillary Electrophoresis, Adv. Pharm. Bull. 5 (2015) 35-40. 
[28] G. Hancu, A. Carje, I. Iuga, I. Fulop, Z.I. Szabo, Cyclodextrine Screening for the Chiral 
Separation of Carvedilol by Capillary Electrophoresis, Iranian J. Pharm. Res. 14 (2015) 425-433. 
[29] T. Ullrich, D. Wesenberg, C. Bleuel, G.J. Krauss, M.G. Schmid, M. Weiss, G. Gubitz, Chiral 
separation of the beta(2)-sympathomimetic fenoterol by HPLC and capillary zone 
electrophoresis for pharmacokinetic studies, Biomed. Chrom. 24 (2010) 1125-1129. 
[30] C. Li, Y. Jiang, Analysis of Repaglinide Enantiomers in Pharmaceutical Formulations by 
Capillary Electrophoresis Using 2,6-Di-o-methyl-beta-cyclodextrin as a Chiral Selector, J. 
Chromatogr. Sci. 50 (2012) 739-743.  
[31] G. Hancu, C. Samarghitan, A. Rusu, E. Mircia, Sotalol chiral separation by capillary 




[32] F.A. Aguiar, C.M. de Gaitani, K.B. Borges, Capillary electrophoresis method for the 
determination of isradipine enantiomers: Stability studies and pharmaceutical formulation 
analysis, Electrophoresis 32 (2011) 2673-2682. 
[33] W.H. Li, L.A. Zhao, G.G. Tan, C.Q. Sheng, X.R. Zhang, Z.Y. Zhu, G.Q. Zhang, Y.F. Chai, 
Enantioseparation of the New Antifungal Drug Iodiconazole and Structurally Related 
Triadimenol Analogues by CE with Neutral Cyclodextrin Additives, Chromatographia 73 (2011) 
1009-1014. 
[34] K.R. Lee, N.T. Nguyen, Y.J. Lee, S. Choi, J.S. Kang, W. Mar, K.H. Kim, Determination of the R-
enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis, Arch. 
Pharm. Res. 38 (2015) 826-833. 
[35] X.L. Deng, B. De Cock, R. Vervoort, D. Pamperin, E. Adams, A. Van Schepdael, Development 
of a Validated Capillary Electrophoresis Method for Enantiomeric Purity Control and Quality 
Control of Levocetirizine in a Pharmaceutical Formulation, Chirality 24 (2012) 276-282. 
[36] A.R. Fakhari, H. Tabani, S. Nojavan, H. Abedi, Electromembrane extraction combined with 
cyclodextrin-modified capillary electrophoresis for the quantification of trimipramine 
enantiomers, Electrophoresis 33 (2012) 506-515. 
[37] H. Tabani, A.R. Fakhari, A. Shahsavani, H.G. Alibabaou, Electrically Assisted Liquid-Phase 
Microextraction Combined with Capillary Electrophoresis for Quantification of Propranolol 
Enantiomers in Human Body Fluids, Chirality 26 (2014) 260-267. 
[38] G. Merola, H.Z. Fu, F. Tagliaro, T. Macchia, B.R. McCord, Chiral separation of 12 cathinone 
analogs by cyclodextrin-assisted capillary electrophoresis with UV and mass spectrometry 
detection, Electrophoresis 35 (2014) 3231-3241. 
[39] Y.D. Qi, X.J. Zhang, Determination of Enantiomeric Impurity of Levamlodipine Besylate Bulk 
Drug by Capillary Electrophoresis Using Carboxymethyl-β-Cyclodextrin, Cell Biochem. Biophys. 
70 (2014) 1633-1637. 
[40] S. Hamidi, S. Soltani, A. Jouyban, A dispersive liquid–liquid microextraction and chiral 
separation of carvedilol in human plasma using capillary electrophoresis, Bioanalysis 7 (2015) 
1107-1117. 
[41] H. Zhu, E. Wu, J. Chen, Y.S. Jang, W. Kang, J.K. Choi, W. Lee, J.S. Kang, Reverse migration 
order of sibutramine enantiomers as a function of cyclodextrin concentration in capillary 
electrophoresis, J. Pharm. Biomed. Anal. 54 (2011) 1007-1012. 
[42] L. Burrai, M. Nieddu, M.A. Pirisi, A. Carta, I. Briguglio, G. Boatto, Enantiomeric Separation of 
13 New Amphetamine-Like Designer Drugs by Capillary Electrophoresis, Using Modified-β-
Cyclodextrins, Chirality 25 (2013) 617-621.  
[43] W.A.W. Ibrahim, S.R. Arsad, H. Maarof, M.M. Sanagi, H.Y. Aboul-Enein, Chiral Separation of 
Four Stereoisomers of Ketoconazole Drugs Using Capillary Electrophoresis, Chirality 27 (2015) 
223-227.  
[44] J.J. Zhang, Y.X. Du, Q. Zhang, J.Q. Chen, G.F. Xu, T. Yu, X.Y. Hu, Investigation of the synergistic 
effect with amino acid-derived chiral ionic liquids as additives for enantiomeric separation in 




[45] F. Sattary, A. Shafaati, A. Zarghi, Improvement of Capillary Electrophoretic 
Enantioseparation of Fluoxetine by a Cationic Additive, Iranian J. Pharm. Res. 12 (2013) 71-76. 
[46] H.B. Xue, Y.N. Jiao, H. Li, Capillary Electrophoresis Separation of the Six Pairs of Chiral 
Pharmaceuticals Enantiomers, Asian J. Chem. 25 (2013) 2742-2746. 
[47] B. Chankvetadze, Enantioseparations by using capillary electrophoretic techniques The 
story of 20 and a few more years, J. Chromatogr. A 1168 (2007) 45-70. 
[48] B. Chankvetadze, Combined approach using capillary electrophoresis and NMR 
spectroscopy for an understanding of enantioselective recognition mechanisms by 
cyclodextrins, Chem. Soc. Rev. 33 (2004) 337-347. 
[49] G.K.E. Scriba, Pharmaceutical and biomedical applications of chiral capillary electrophoresis 
and capillary electrochromatography: An update, Electrophoresis 24 (2003) 2409-2421. 
[50] B. Chankvetadze, Enantiomer migration order in chiral capillary electrophoresis, 
Electrophoresis 23 (2002) 4022-4035. 
[51] B. Chankvetadze, Separation of enantiomers with charged chiral selectors in CE, 
Electrophoresis 30 (2009) S211-S221. 
[52] S. Wongwan, B. Sungthong, G.K.E. Scriba, CE assay for simultaneous determination of 
charged and neutral impurities in dexamphetamine sulfate using a dual CD system, 
Electrophoresis 31 (2010) 1475-1481. 
[53] E. Lipka, C. Danel, S. Yous, J.P. Bonte, C. Vaccher, Dual CD system in capillary electrophoresis 
for direct separation of the four stereoisomers of agonist and antagonist melatoninergic ligands, 
Electrophoresis 31 (2010) 1529-1532. 
[54] J. Yu, Y.F. Zhao, J.X. Song, X.J. Guo, Enantioseparation of meptazinol and its three 
intermediate enantiomers by capillary electrophoresis using a new cationic β-cyclodextrin 
derivative in single and dual cyclodextrin systems, Biomed. Chromatogr. 28 (2014) 868-874. 
[55] Y. Jin, C. Chen, L.C. Meng, J.T. Chen, M.X. Li, Z.W. Zhu, Simultaneous and sensitive capillary 
electrophoretic enantioseparation of three β-blockers with the combination of achiral ionic 
liquid and dual CD derivatives, Talanta 89 (2012) 149-154. 
[56] Y. Iwamuro, R. Iio-Ishimaru, S. Chinaka, N. Takayama, S. Kodama, K. Hayakawa, 
Reproducible chiral capillary electrophoresis of methamphetamine and its related compounds 
using a chemically modified capillary having diol groups, Forensic Toxicol. 28 (2010) 19-24. 
[57] Y. Cui, X.W. Ma, M. Zhao, Z. Jiang, S.Y. Xu, X.J. Guo, Combined Use of Ionic Liquid and 
Hydroxypropyl-β-Cyclodextrin for the Enantioseparation of Ten Drugs by Capillary 
Electrophoresis, Chirality 25 (2013) 409-414. 
[58] L.H. Zuo, H. Meng, J.J. Wu, Z. Jiang, S.Y. Xu, X.J. Guo, Combined use of ionic liquid and β-CD 
for enantioseparation of 12 pharmaceuticals using CE, J. Sep. Sci. 36 (2013) 517-523. 
[59] M. Zhao, Y. Cui, J. Yu, S.Y. Xu, X.J. Guo, Combined use of hydroxypropyl-β-cyclodextrin and 
ionic liquids for the simultaneous enantioseparation of four azole antifungals by CE and a study 




[60] F.O. Suliman, A.A. Elbashir, O.J. Schmitz, Study on the separation of ofloxacin enantiomers 
by hydroxylpropyl-beta-cyclodextrin as a chiral selector in capillary electrophoresis: a 
computational approach, J. Incl. Phenom. Macrocycl. Chem. 83 (2015) 119-129. 
[61] T. Yu, Y.X. Du, J.Q. Chen, G.F. Xu, K. Yang, Q. Zhang, J.J. Zhang, S.J. Du, Z.J. Feng, Y.J. Zhang, 
Study on clarithromycin lactobionate based dual selector systems for the enantioseparation of 
basic drugs in capillary electrophoresis, J. Sep. Sci. 38 (2015) 2900-2906. 
[62] J.Q. Chen, Y.X. Du, F.X. Zhu, B. Chen, Evaluation of the enantioselectivity of glycogen-based 
dual chiral selector systems towards basic drugs in capillary electrophoresis, J. Chromatogr. A 
1217 (2010) 7158-7163. 
[63] M. Moini, C.M. Rollman, Compatibility of highly sulfated cyclodextrin with electrospray 
ionization at low nanoliter/minute flow rates and its application to capillary 
electrophoresis/electrospray ionization mass spectrometric analysis of cathinone derivatives 
and their optical isomers, Rapid Commun. Mass Spectrom. 29 (2015) 304-310. 
[64] Y.T. Iwata, T. Mikuma, K. Kuwayama, K. Tsujikawa, H. Miyaguchi, T. Kanamori, H. Inoue, 
Applicability of chemically modified capillaries in chiral capillary electrophoresis for 
methamphetamine profiling, Forensic Sci. Int. 226 (2013) 235-239. 
[65] T. Mikuma, Y.T. Iwata, H. Miyaguchi, K. Kuwayama, K. Tsujikawa, T. Kanamori, H. Inoue, The 
use of a sulfonated capillary on chiral capillary electrophoresis/mass spectrometry of 
amphetamine-type stimulants for methamphetamine impurity profiling, Forensic Sci. Int. 249 
(2015) 59-65. 
[66] A.C. Servais, A. Rousseau, M. Fillet, K. Lomsadze, A. Salgado, J. Crommen, B. Chankvetadze, 
Separation of propranolol enantiomers by CE using sulfated beta-CD derivatives in aqueous and 
non-aqueous electrolytes: Comparative CE and NMR study, Electrophoresis 31 (2010) 1467-
1474. 
[67] L. Chankvetadze, A.C. Servais, M. Fillet, A. Salgado, J. Crommen, B. Chankvetadze, 
Comparative enantioseparation of talinolol in aqueous and non-aqueous capillary 
electrophoresis and study of related selector–selectand interactions by nuclear magnetic 
resonance spectroscopy, J. Chromatogr. A 1267 (2012) 206-216. 
[68] Y. Feng, T.T. Wang, Z.J. Jiang, B. Chankvetadze, J. Crommen, Comparative enantiomer 
affinity pattern of β-blockers in aqueous and nonaqueous CE using single-component anionic 
cyclodextrins, Electrophoresis 36 (2015) 1358-1364. 
[69] W.P. Guo, Z.B. Rong, Y.H. Li, Y.S. Fung, G.Q. Gao, Z.M. Cai, Microfluidic chip capillary 
electrophoresis coupled with electrochemiluminescence for enantioseparation of racemic drugs 
using central composite design optimization, Electrophoresis 34 (2013) 2962-2969. 
[70] L. Asensi-Bernardi, L. Escuder-Gilabert, Y. Martin-Biosca, S. Sagrado, M.J. Medina-
Hernández, Characterizing the interaction between enantiomers of eight psychoactive drugs 
and highly sulfated-beta-cyclodextrin by counter-current capillary electrophoresis, Biomed. 
Chrom. 28 (2014) 120-126. 
[71] A.C. Servais, A. Rousseau, M. Fillet, K. Lomsadze, A. Salgado, J. Crommen, B. Chankvetadze, 
Capillary electrophoretic and nuclear magnetic resonance studies on the opposite affinity 





[72] K. Lomsadze, A. Salgado, E. Calvo, J.A. Lopez, B. Chankvetadze, Comparative NMR and MS 
studies on the mechanism of enantioseparation of propranolol with heptakis(2,3-diacetyl-6-
sulfo)-beta-cyclodextrin in capillary electrophoresis with aqueous and nonaqueous electrolytes, 
Electrophoresis 32 (2011) 1156-1163. 
[73] E.D. Vega, K. Lomsadze, L. Chankvetadze, A. Salgado, G.K.E. Scriba, E. Calvo, J.A. Lopez, A.L. 
Crego, M.L. Marina, B. Chankvetadze, Separation of enantiomers of ephedrine by capillary 
electrophoresis using cyclodextrins as chiral selectors: Comparative CE, NMR and high resolution 
MS studies, Electrophoresis 32 (2011) 2640-2647. 
[74] K. Lomsadze, E.D. Vega, A. Salgado, A.L. Crego, G.K.E. Scriba, M.L. Marina, B. Chankvetadze, 
Separation of enantiomers of norephedrine by capillary electrophoresis using cyclodextrins as 
chiral selectors: Comparative CE and NMR studies, Electrophoresis 33 (2012) 1637-1647. 
[75] Y.J. Lee, S. Choi, J. Lee, N. Nguyen, K. Lee, J.S. Kang, W. Mar, K.H. Kim, Chiral discrimination 
of sibutramine enantiomers by capillary electrophoresis and proton nuclear magnetic resonance 
spectroscopy, Arch. Pharm. Res. 35 (2012) 671-681. 
[76] S. Samakashvili, A. Salgado, G.K.E. Scriba, B. Chankvetadze, Comparative Enantioseparation 
of Ketoprofen with Trimethylated α-, β-, and γ-Cyclodextrins in Capillary Electrophoresis and 
Study of Related Selector–Selectand Interactions Using Nuclear Magnetic Resonance 
Spectroscopy, Chirality 25 (2013) 79-88. 
[77] E. Sánchez-López, A. Salgado, A.L. Crego, M.L. Marina, Investigation on the 
enantioseparation of duloxetine by capillary electrophoresis, NMR, and mass spectrometry, 
Electrophoresis 35 (2014) 2842-2847.  
[78] A.C. Servais, A. Rousseau, G. Dive, M. Frederich, J. Crommen, M. Fillet, Combination of 
capillary electrophoresis, molecular modelling and nuclear magnetic resonance to study the 
interaction mechanisms between single-isomer anionic cyclodextrin derivatives and basic drug 
enantiomers in a methanolic background electrolyte, J. Chromatogr. A 1232 (2012) 59-64. 
[79] W.H. Li, G.G. Tan, L. Zhao, X.F. Chen, X.R. Zhang, Z.Y. Zhu, Y.F. Chai, Computer-aided 
molecular modeling study of enantioseparation of iodiconazole and structurally related 
triadimenol analogues by capillary electrophoresis: Chiral recognition mechanism and 
mathematical model for predicting chiral separation, Anal. Chim. Acta 718 (2012) 138-147. 
[80] M.A. Tonon, P.S. Bonato, Capillary electrophoretic enantioselective determination of 
zopiclone and its impurities, Electrophoresis 33 (2012) 1606-1612. 
[81] S. Wongwan, G.K.E. Scriba, Development and validation of a capillary electrophoresis assay 
for the determination of the stereoisomeric purity of chloroquine enantiomers, Electrophoresis 
32 (2011) 2669-2672. 
[82] L. Sánchez-Hernández, M. Guijarro-Díez, M.L. Marina, A.L. Crego, New approaches in 
sensitive chiral CE, Electrophoresis 35 (2014) 12-27. 
[83] E. Sánchez-López, M.L. Marina, A.L. Crego, Improving the sensitivity in Chiral Capillary 
Electrophoresis, Electrophoresis 37 (2016) 19-34. 
[84] M. Castro-Puyana, I. Lammers, J. Buijs, C. Gooijer, F. Ariese, Sensitized phosphorescence as 
detection method for the enantioseparation of bupropion by capillary electrophoresis, 




[85] L. Sanchez-Hernandez, C. Garcia-Ruiz, A.L. Crego, M.L. Marina, Sensitive determination of 
d-carnitine as enantiomeric impurity of levo-carnitine in pharmaceutical formulations by 
capillary electrophoresis–tandem mass spectrometry, J. Pharm. Biomed. Anal. 53 (2010) 1217-
1223. 
[86] E. Sanchez-Lopez, C. Montealegre, M.L. Marina, A.L. Crego, Development of chiral 
methodologies by capillary electrophoresis with ultraviolet and mass spectrometry detection for 
duloxetine analysis in pharmaceutical formulations, J. Chromatogr. A 1363 (2014) 356-362. 
[87] S. Nojavan, A.R. Fakhari, Electro membrane extraction combined with capillary 
electrophoresis for the determination of amlodipine enantiomers in biological samples, J. Sep. 
Sci. 33 (2010) 3231-3238. 
[88] L. Meng, B. Wang, F. Luo, G.J. Shen, Z.Q. Wang, M. Guo, Application of dispersive liquid–
liquid microextraction and CE with UV detection for the chiral separation and determination of 
the multiple illicit drugs on forensic samples, Forensic Sci. Int. 209 (2011) 42-47. 
[89] S. Portmann, H.Y. Kwan, R. Theurillat, A. Schmitz, M. Mevissen, W. Thormann, 
Enantioselective capillary electrophoresis for identification and characterization of human 
cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro, J. Chromatogr. 
A 1217 (2010) 7942-7948. 
[90] H.Y. Kwan, W. Thormann, Enantioselective capillary electrophoresis for the assessment of 
CYP3A4-mediated ketamine demethylation and inhibition in vitro, Electrophoresis 32 (2011) 
2738-2745. 
[91] H.Y. Kwan, W. Thormann, Electrophoretically mediated microanalysis for characterization 
of the enantioselective CYP3A4 catalyzed N-demethylation of Ketamine, Electrophoresis 33 
(2012) 3299-3305. 
[92] R. Reminek, Z. Glatz, W. Thormann, Optimized on-line enantioselective capillary 
electrophoretic method for kinetic and inhibition studies of drug metabolism mediated by 
cytochrome P450 enzymes, Electrophoresis 36 (2015) 1349-1357. 
[93] A. Schmitz, W. Thormann, L. Moessner, R. Theurillat, K. Helmja, M. Mevissen, 
Enantioselective CE analysis of hepatic ketamine metabolism in different species in vitro, 
Electrophoresis 31 (2010) 1506-1516. 
[94] R. Theurillat, M.P. Larenza, K. Feige, R. Wolfensberger, W. Thormann, Development of a 
method for analysis of ketamine and norketamine enantiomers in equine brain and 





Figure 1. An electropherogram demonstrates the reversal of sibutramine enantiomer migration 
order using (a) native β-CD and (b) A-β-CD as chiral selectors. CE conditions: fused-silica capillary 
(uncoated, 50 µm i.d. x 54 cm, effective length 45 cm); injection, 50 mbar, 5 s; applied voltage, 
251<V; temperature, 25 °C; buffer, 20 mM phosphate/10 mM citrate containing chiral selector, 
pH 4.3; detection, 223 nm. The highest concentration of β-CD and A-β-CD used in this 
experiment was 20 and 100 mM, respectively. (From ref. [41]) 
 
Figure 2. The electropherograms of enantiomeric separation of meptazinol and its three 
intermediates using single CD system. (A) Intermediate II; background electrolyte (BGE), 12.5 
mmol/L mono-6-deoxy-6-piperdine-β-CD (PIP-β-CD), pH 3.0, 20 mmol/L phosphate buffer, 20 
kV. (B) Meptazinol, intermediate III and intermediate IV; BGE, 7.5 mmol/L PIP-β-CD, pH 3.0, 20 
mmol/L phosphate buffer, 20 kV. The electropherograms of enantiomeric separation of 
meptazinol, intermediate III and intermediate IV using HP-β-CD (HP- β-CD) and PIP-β-CD dual CD 
system. (C) BGE: 4.0 mmol/L HP-β-CD and 5.0 mmol/L PIP-β-CD, pH 3.0, 20 mmol/L phosphate 
buffer, 20 kV. (D) BGE: 40.0 mmol/L HP-β-CD and 5.0 mmol/L PIP-β-CD, pH 3.0, 20 mmol/L 









Figure 3. Electropherograms of the 10 analytes in the absence (A) and presence (B) of 1-ethyl-3-
methylimidazolium-L-lactate in BGE (BGE: 40 mM HP-β-CD, 50 mM NaH2PO4-H3PO4, pH 2.75 with 
30 mM 1-ethyl-3-methylimidazolium-L-lactate added); ofloxacin (1), propranolol (2), 
dioxopromethazine (3), isoprenaline (4), chlorpheniramine (5), liarozole (6), tropicamide (7), 
amlodipine (8), brompheniramine (9), and homatropine (10). (From ref. [57]) 
 
Figure 4. Typical electropherograms of (A) 60 µM anisodamine (AN), 50 µM atenolol (AT) and 30 
µM metoprolol (ME) standard solutions; (B) 30-fold diluted blank urine sample, (C) 30-fold 
diluted urine spiked with AN, AT, and ME to the same conditions as (A); microchip-CE-ECL 
conditions: separation channel, around 55 cm effective length; sample injection, 10 kV × 10 s; 
separation voltage, 17.5 kV; running buffer, 57.6 mM HAc-NaAc (pH 5.3) − 14.7 mM CM-β-CD. 











Figure 5. Structure of the norephedrine complexes with α-CD (A), β-CD (B), HDMS-β-CD (C), and 












Figure 7. Electropherograms obtained after EME, (A) nonspiked urine sample, and (B) urine 
ample spiked with 100 ng/mL of each enantiomer. CE conditions: capillary: 60 cm (50 cm 
effective length) x 50 µm i.d; detection: 214 nm; applied voltage: 18 kV; temperature: 20° C; 
injection: 60 mbar x 5 s; separation solution: 80 mM ammonium acetate pH 2.5 containing 8mM 






Figure 8. Representative electropherograms for the biotransformation of zopiclone (ZO) by the 
Cunninghcimella fungi after DLLME extraction. (A) Czapek liquid culture medium in the absence 
of ZO (sample control); (B) analysis of the Czapek liquid culture medium after the 
biotransformation period. (IS) Internal standard (rac-mirtazapine), ZO (zopiclone), N-Des-ZO (N-








Figure 9. Norketamine enantiomer formation rate as function of ketamine enantiomer 
concentration by CYP3A4 after 8 min incubation with racemic ketamine at 37°C. Symbols denote 
the mean of duplicates. Solid and dotted lines are predicted values based on nonlinear 
regression analysis using the Michaelis-Menten equation and assuming a twofold dilution of the 





Table 1.- CDs employed in chiral CE for the enantiomeric separation of drugs and resolution values obtained (NR: unresolved, R: partially or totally resolved). 
CD  Drug (Resolution) Ref. 
α-CD amlodipine (1.4), chloroquine (NR), ephedrine (R), ibuprofen (NR), iodiconazole (NR), mefloquine (NR), methoxytolterodine (NR), 
naproxen (NR), norephedrine (R), ornidazole (NR), primaquine(NR), propranolol (0.1), propranolol (NR), quinacrine (NR), quinocide 




β-CD 1-(4-methoxyphenyl)-2-(methylamine)ethanol (NR), 2-amino-1-phenyl-ethanol (NR), 1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-
one (R), 4-fluoromethcathinone (NR), amlodipine (0.86), amlodipine (NR), amphetamine (R), bambuterol (NR), brompheniramine 
(1.30), buphedrone (R), bupivacaine (NR), butylone (NR), carvedilol (2.74), carvedilol (1.12), cetirizine (NR), chloroquine (NR), 
chlorphenamine (1.16), citalopram (NR), clenbuterol (1.85), dimethylcathinone (R), dioxopromethazine (1.28), duloxetine (NR), 
duloxetine (NR), ephedrine (R), ethcathinone (R), ethylone (R), fenoterol (R), homatropine (1.21), homatropine (1.97), ibuprofen (0.8), 
iodiconazole (NR), iodiconazole (NR), ketamine (R), liarozole (1.45), 1-(Benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (R), 
mefloquine (0.30), mephedrone (R), mephedrone (NR), methamphetamine (R), methedrone (NR), methoxytolterodine (NR), 
methylenedioxymethamphetamine (R), methylone (R), naphyrone (NR), naproxen (0.5), nefopam (NR), norephedrine (R), ofloxacin 
(NR), ornidazole (NR), pentedrone (R), pentylone (R), primaquine (NR), procaterol (2.52), promethazine (1.15), propranolol (0.6), 
propranolol (R), quinacrine (NR), quinocide (NR), repaglinide (1.18), repaglinide (NR), salbutamol (NR), salbutamol (NR), sibutramine 
(0.92), sibutramine (1.1), sotalol (NR), sotalol (NR), tafenoquine (NR), talinolol (NR), tamsulosin (1.4), tolterodine (NR), trimipramine 







γ-CD bambuterol (NR), butylone (NR), chloroquine (NR), clenbuterol (NR), duloxetine (NR), ephedrine (NR), fenoterol (NR), ibuprofen (NR), 
iodiconazole (NR), iodiconazole (NR), mefloquine (NR), mephedrone (NR), methoxytolterodine (NR), naphyrone (NR), naproxen (NR), 
norephedrine (NR), ornidazole (NR), primaquine (1.02), procaterol (0.46), propranolol (NR), quinacrine (NR), quinocide (NR), 






A-β-CD duloxetine (NR), sibutramine (2.86), valsartan (3.08) 34,41,86 
A-γ-CD duloxetine (R), duloxetine (0.6) 77,86 
CE-α-CD chloroquine (NR), mefloquine (0.72), primaquine (NR), quinacrine (NR), quinocide (NR), tafenoquine (NR) 16 
CE-β-CD ornidazole (NR), chloroquine (NR), mefloquine (1.53), primaquine (NR), quinacrine (NR), quinocide (0.95), tafenoquine (NR) 16,21 
CE-γ-CD chloroquine (NR), mefloquine (0.73), primaquine (3.32), quinacrine (NR), quinocide (NR), tafenoquine (NR) 16 
CM-α-CD chloroquine (1.86), mefloquine (3.64), primaquine (19.64), quinacrine (NR), quinocide (0.45), tafenoquine (1.26) 16 
CM-β-CD 1-(4-methoxyphenyl)-2-(methylamine)ethanol (R), 2-amino-1-phenyl-ethanol (R), amlodipine (1.55), amlodipine (9.8), anisodamine (R), 
atenolol (R), bambuterol (8.52), butylone (0.3), carvedilol (4.0), chloroquine (1.09), clenbuterol (7.65), desmethylzopiclone (> 2), 
isradipine (R), mefloquine (6.24), mephedrone (NR), meptazinol (2.03), methoxytolterodine (NR), metoprolol (R), naphyrone (1.9), 
primaquine (2.05), procaterol (25.37), quinacrine (1.67), quinocide (2.51), salbutamol (2.19), salbutamol (R), sibutramine (1.6), sotalol 







CM-γ-CD chloroquine (NR), mefloquine (2.85), primaquine (9.18), quinacrine (NR), quinocide (1.00), tafenoquine (0.51) 16 
DM-β-CD duloxetine (NR), iodiconazole (NR), bambuterol (1.45), clenbuterol (3.07), ephedrine (R), fenoterol (NR), iodiconazole (NR), 
methoxytolterodine (NR), norephedrine (R), procaterol (4.82), propranolol (NR), repaglinide (1.8), salbutamol (0.97), talinolol (NR), 




Glu-β-CD naproxen (1.04), pranoprofen (NR), warfarin (0.62) 60 
HB-β-CD duloxetine (R), duloxetine (0.7) 77,86 
HB-γ-CD duloxetine (NR) 86 
HDA-β-CD ephedrine (R), norephedrine (R) 73,74 
HDAS-β-CD propranolol (R), acebutolol (< 1), atenolol (< 1), bupivacaine (R), carazolol (3.6), carteolol (2.9), carvedilol (1.3), ephedrine (R), 
norephedrine (R), propranolol (R), propranolol (R), propranolol (R), propranolol (3.9), sotalol (6.5), talinolol (R) 
66,67,68,71,72 
73,74,78 
HDMS-β-CD propranolol (R), acebutolol (1.2), atenolol (< 1), bupivacaine (R), carazolol (< 1), carteolol (< 1), carvedilol (< 1), ephedrine (R), 
norephedrine (R), propranolol (R), propranolol (R), propranolol (R), propranolol (3.3), sotalol (1.5), talinolol (R) 
66,67,68,71,72 
73,74,78 
HE-β-CD iodiconazole (NR), methoxytolterodine (NR), tolterodine (NR) 23,33 
HP-α-CD propranolol (0.3), chloroquine (NR), iodiconazole (NR), mefloquine (2.84), primaquine (1.46), quinacrine (NR), quinocide (NR), 
tafenoquine (NR), trimipramine (1.1), valsartan (NR) 
16,34,36,37,79 
HP-β-CD amlodipine (2.17), amlodipine (R), amlodipine (2.33), bambuterol (0.57), bupivacaine (NR), butylone (NR), carvedilol (2.54), cetirizine 
(NR), chloroquine (NR), citalopram (NR), clenbuterol (0.45), duloxetine (> 1), duloxetine (NR), duloxetine (1.6), fenoterol (R), 
iodiconazole (NR), iodiconazole (NR), mefloquine (2.34), mephedrone (NR), methoxytolterodine (NR), naphyrone (NR), naproxen (1.95), 
nefopam (0.5), ofloxacin (R), pranoprofen (< 0.40), primaquine (NR), procaterol (5.56), propranolol (1.2), quinacrine (NR), quinocide 
(0.95), salbutamol (0.74), sibutramine (0.9), sotalol (0.73), tafenoquine (NR), tolterodine (NR), trimipramine (0.3), tulobuterol (1.18), 






HP-γ-CD chloroquine (NR), iodiconazole (2.69), iodiconazole (1.26), mefloquine (0.84), methoxytolterodine (NR), primaquine (3.24), quinacrine 
(NR), quinocide (NR), tafenoquine (NR), tolterodine (NR) 
16,23,33,79 
HS-β-CD bupropion (8.8), dimethindene (21.5), ephedrine (R), fluoxetine (11.1), nomifensine (34.1), orphenadrine (6.3), promethazine (6.4), 
propranolol (R), terfenadine (< 1.5), viloxazine (2.8) 
70,71,73 
HS-γ-CD 1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one (R), 4-fluoromethcathinone (R), amphetamine (R), amphetamine (R), 
buphedrone (NR), dimethylamphetamine (R), dimethylcathinone (NR), ephedrine (R), ephedrine (R), ethcathinone (NR), ethylone (R), 
ketamine (R), ketamine (R), ketamine (R), 1-(Benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (R), mephedrone (R), 
methamphetamine (R), methamphetamine (R), methedrone (R), methylenedioxyamphetamine (R), methylenedioxyethylamphetamine 
(R), methylenedioxymethamphetamine (R), methylephedrine (R), methylone (R), norephedrine (R), norephedrine (R), norketamine (R), 
norketamine (R), norketamine (R), norpseudoephedrine (R), norpseudoephedrine (R), pentedrone (NR), pentylone (R), 
pseudoephedrine (R), pseudoephedrine (R) 
38,64,65,90,91 
92 
M-β-CD atenolol (NR), bisoprolol (NR), duloxetine (NR), esmolol (NR), metoprolol (NR), naproxen (0.52), pranoprofen (< 0.40), propranolol (NR), 






M-γ-CD duloxetine (> 1), duloxetine (NR), duloxetine (1.6) 77,86 
P-α-CD methoxytolterodine (NR), tolterodine (NR) 23 
P-β-CD methoxytolterodine (NR), tolterodine (NR) 23 
P-γ-CD methoxytolterodine (3.0), tolterodine (4.0) 23 
PIP-β-CD meptazinol (0.80) 54 
RAMEB amlodipine (2.48), carvedilol (1.98), chloroquine (NR), mefloquine (2.05), primaquine (NR), quinacrine (NR), quinocide (NR), sotalol 
(1.39), tafenoquine (NR) 
16,27,28,31 
S-α-CD bupropion (> 3), chloroquine (NR), mefloquine (1.65), methoxytolterodine (2.0), ornidazole (R), primaquine (2.38), quinacrine (1.36), 
quinocide (NR), tafenoquine (NR), tolterodine (3.0 
16,21,23,84 
S-β-CD 2, 5-dimethoxy-4-bromoamphetamine (9.3), 2,3,4-trimethoxyamphetamine (1.4), 2,4,5-trimethoxyamphetamine (1.3), 2,4,6-
trimethoxyamphetamine (2.5), 2,5-dimethoxy-4-chloroamphetamine (5.5), 2,5-dimethoxy-4-ethylamphetamine (2.6), 2,5-dimethoxy-4-
iodoamphetamine (1.9), 2,5-dimethoxy-4-methylamphetamine (6.0), 2,5-dimethoxy-4-nitroamphetamine (1.1), 2,5-dimethoxy-4-
propylamphetamine (2.8), 3,4,5-trimethoxyamphetamine (1.1), 3,4-dimethylmethcathinone (4.8), 3-fluoromethcathinone (1.9), 4-
bromomethcathinone (0.9), 4-fluoromethcathinone (0.8), 4-methylethcathinone (2.7), α-pyrrolidinopropiophenone (2.1), 
amphetamine (> 3), buphedrone (1.2), butylone (2.3), cathinone (0.9), cetirizine (1.52), cetirizine (> 3), chloroquine (R), chloroquine 
(3.61), ethcathinone (1.3), ethylbuphedrone (1.8), ethylone (1.4), fluoxetine (R), hydroxyzine (1.76), isradipine (NR), ketamine (R), 
ketamine (R), ketamine (R), ketamine (R), mefloquine (9.85), mephedrone (2.3), meptazinol (NR), methcathinone (0.9), methedrone 
(0.0), methoxyamphetamine (1.5), methoxymethamphetamine (2.2), methoxytolterodine (11.0), methylendioxypyrovalerone (1.0), 
methylone (1.6), naphyrone (2.6), norketamine (R), norketamine (R), norketamine (R), norketamine (R), ofloxacin (5.45), ornidazole (R), 





S-γ-CD chloroquine (0.85), mefloquine (1.90), primaquine (8.09), quinacrine (0.69), quinocide (NR), tafenoquine (NR) 16 
SBE-α-CD chloroquine (1.06), mefloquine (1.18), primaquine (1.07), quinacrine (1.41), quinocide (NR), tafenoquine (0.77) 16 
SBE-β-CD amlodipine (2.59), amphetamine (R), bupivacaine (R), carvedilol (1.03), chloroquine (R), chloroquine (0.5), isradipine (> 6), mefloquine 
(1.70), ornidazole (R), primaquine (5.87), quinacrine (2.26), quinocide (NR), repaglinide (R), sotalol (0.70), tafenoquine (NR) 
16,27,28,32,52 
20,21,30,31,81 
SBE-γ-CD chloroquine (NR), mefloquine (5.55), primaquine (8.36), quinacrine (NR), quinocide (NR), tafenoquine (NR) 16 
SP-β-CD ornidazole (R) 21 
Succ-β-CD chloroquine (1.08), mefloquine (1.35), primaquine (0.68), quinacrine (NR), quinocide (1.07), tafenoquine (NR) 16 
Succ-γ-CD carnitine (≈ 3) 85 
TA-β-CD duloxetine (NR) 86 
TA-γ-CD duloxetine (NR) 86 
TM-α-CD ketoprofen (1.30) 76 
TM-β-CD duloxetine (NR), iodiconazole (R), bambuterol (NR), chloroquine (NR), clenbuterol (NR), ephedrine (R), fenoterol (R), iodiconazole 
(0.67), ketoconazole (R), ketoprofen (1.70), mefloquine (NR), norephedrine (R), primaquine (1.03), procaterol (NR), propranolol (R), 







TM-γ-CD ketoprofen (2.50) 76 
 
 
Table 2.- Comparison of the best enantioresolution reported for chiral drugs using neutral and anionic β-CDs (NR: unresolved, R: partially or totally resolved). 
Drug Neutral β-CDs (Resolution) Anionic β-CDs (Resolution) Ref. 
1-(4-methoxyphenyl)-2-(methylamine)ethanol β-CD (NR) CM-β-CD* (R) 26 
2-amino-1-phenyl-ethanol β-CD (NR) CM-β-CD (R) 26 
4-fluoromethcathinone β-CD (NR) S-β-CD (0.8) 17,38 
amlodipine β-CD (0.86), RAMEB (2.48), HP-β-CD (2.33), CM-β-CD (9.8) SBE-β-CD (2.59) 27,39,62 
atenolol M-β-CD (NR) CM-β-CD (R) 61,69 
butylone β-CD (NR), HP-β-CD (NR) CM-β-CD (0.39, S-β-CD (2.3) 17 
carvedilol β-CD (2.74), RAMEB (1.98), HP-β-CD (2.54), CM-β-CD (4.0) SBE-β-CD (1.03) 28,40 
cetirizine β-CD (NR), HP-β-CD (NR) S-β-CD (> 3) 35,62 
chloroquine β-CD (NR), RAMEB (NR), TM-β-CD (NR), HP-β-CD (NR), CM-β-CD (1.09), 
CE-β-CD (NR), Succ-β-CD (1.08) 
S-β-CD (3.61), SBE-β-CD (R) 16,81 
mefloquine β-CD (0.30), RAMEB (2.05), TM-β-CD (NR), HP-β-CD (2.34), CM-β-CD 
(6.24), CE-β-CD (1.53), Succ-β-CD (1.35) 
S-β-CD (9.85), SBE-β-CD (1.70) 16 
mephedrone β-CD (NR), HP-β-CD (NR), CM-β-CD (NR) S-β-CD (2.3) 17 
methoxytolterodine β-CD (NR), DM-β-CD (NR), HE-β-CD (NR), HP-β-CD (NR), CM-β-CD (NR) S-β-CD (11.0), P-β-CD (NR) 23 
metoprolol M-β-CD (NR) CM-β-CD (R) 61,69 
naphyrone β-CD (NR), HP-β-CD (NR), CM-β-CD (1.9) S-β-CD (2.6) 17 
ofloxacin β-CD (NR), HP-β-CD (R) S-β-CD (5.45) 15,44 
ornidazole β-CD (NR), CE-β-CD (NR) S-β-CD (6.28), SBE-β-CD (R) 15,21 
primaquine β-CD (NR), RAMEB (NR), TM-β-CD (1.03), HP-β-CD (NR), CM-β-CD (2.05), 
CE-β-CD (NR), Succ-β-CD (0.68) 
S-β-CD (0.86), SBE-β-CD (5.87) 16 
promethazine β-CD (1.15) HS-β-CD (6.4) 58,70 
quinacrine β-CD (NR), RAMEB (NR), TM-β-CD (NR), HP-β-CD (NR), CM-β-CD (1.67), 
CE-β-CD (NR), Succ-β-CD (NR) 
S-β-CD (NR), SBE-β-CD (2.26) 16 
quinocide β-CD (NR), RAMEB (NR), TM-β-CD (NR), HP-β-CD (0.95), CM-β-CD (2.51), 
CE-β-CD (0.95), Succ-β-CD (1.07) 
S-β-CD (0.68), SBE-β-CD (NR) 16 




sibutramine β-CD (1.1), M-β-CD (1.48), HP-β-CD (0.9), A-β-CD (2.86) CM-β-CD (1.6) 18,41,75 
sotalol β-CD (NR), RAMEB (1.39), HP-β-CD (0.73), CM-β-CD (NR) CM-β-CD (R), SBE-β-CD (0.70) 26,31 
tafenoquine β-CD (NR), RAMEB (NR), TM-β-CD (0.68), HP-β-CD (NR), CM-β-CD (1.44), 
CE-β-CD (NR), Succ-β-CD (NR) 
S-β-CD (NR), SBE-β-CD (NR) 16 
tolterodine β-CD (NR), DM-β-CD (NR), HE-β-CD (NR), HP-β-CD (NR), CM-β-CD (NR) S-β-CD (13.0), P-β-CD (NR) 23 
 








Table 3.- Dual chiral systems employed in chiral CE for the enantiomeric separation of drugs (NR: not resolved, R: partially or totally resolved). 
Chiral selectors Drug (Resolution) Ref. 
SBE-β-CD + S-β-CD amphetamine (R) 52 
β-CD + CM-β-CD 
CM-β-CD + HP-β-CD 
desmethylzopiclone (> 2), zopiclone (> 2), zopicloneoxide (> 2) 
desmethylzopiclone (> 2), zopiclone (> 2), zopicloneoxide (> 2) 
25 
HS-β-CD + α-CD 
HS-β-CD + γ-CD 
HS-β-CD + HP-α-CD 
HS-α-CD + HP-γ-CD 
tetrahydronaphthalenic derivatives (R) 
tetrahydronaphthalenic derivatives (R) 
tetrahydronaphthalenic derivatives (R) 
tetrahydronaphthalenic derivatives (R) 
53 
β-CD + PIP-β-CD 
HP-β-CD + PIP-β-CD 





DM-β-CD + TM-β-CD oxprenolol (0.9), pindolol (1.4), propranolol (1.1) 55 
β-CD + DM-β-CD amphetamine (R), dimethylamphetamine (R), ephedrine (R), hydroxymethamphetamine (R), methamphetamine (R), 
methylenedioxyamphetamine (R), methylenedioxyethylamphetamine (R), methylenedioxymethamphetamine (R), methylephedrine 
(R), norephedrine (R), 
56 
HP-β-CD + [EMIm][L-lactate] amlodipine (4.35), brompheniramine (2.76), chlorpheniramine (2.88), dioxopromethazine (1.85), homatropine (2.98), isoprenaline 
(2.48), liarozole (1.43), ofloxacin (5.35), propranolol (1.76), tropicamide (5.45) 
57 
β-CD + [EMIm][L-lactate] 
 
β-CD + [EMIm]Br 
brompheniramine (4.52), carvedilol (3.50), chlorphenamine (3.04), dioxopromethazine (1.57), homatropine (1.63), homatropine 
(3.06), liarozole (2.62), promethazine (1.98), repaglinide (2.13), sibutramine (1.44), venlafaxine (1.26), zopiclone (5.20) 
brompheniramine (3.57), carvedilol (2.3), chlorphenamine (2.48), dioxopromethazine (1.19), homatropine (1.54), homatropine 
(2.99), liarozole (1.55), promethazine (1.41), repaglinide (1.28), sibutramine (1.24), venlafaxine (0.92), zopiclone (3.17) 
58 
HP-β-CD + DTAC econazole (3.5), itraconazole (2.5), ketoconazole (2.8), miconazole (3.8) 59 
Glu-β-CD + L-AlaC4NTf2 
HP-β-CD + L-AlaC4NTf2 
M-β-CD + L-AlaC4NTf2 
Glu-β-CD + L-ValC4NTf2 
HP-β-CD + L-ValC4NTf2 
M-β-CD + L-ValC4NTf2 
naproxen (2.58), pranoprofen (0.50), warfarin (0.63) 
naproxen (3.80), pranoprofen (0.60), warfarin (0.67) 
naproxen (1.56), pranoprofen (1.68), warfarin (0.50) 
naproxen (1.95), pranoprofen (0.90), warfarin (0.67) 
naproxen (3.28), pranoprofen (0.58), warfarin (0.85) 
naproxen (1.51), pranoprofen (1.40), warfarin (0.50) 
60 
M-β-CD + clarithromycin 
Glu-β-CD + clarithromycin 
HE-β-CD + clarithromycin 
HP-β-CD + clarithromycin 








β-CD + glycogen 
HP-β-CD + glycogen 
amlodipine (NR), cetirizine (NR), citalopram (NR), duloxetine (NR), nefopam (NR) 
amlodipine (1.97), cetirizine (NR), citalopram (NR), duloxetine (0.42), nefopam (NR) 
62 
HS-γ-CD + (+)-18-C-6-TCA 3-fluoromethcathinone (R), 4-fluoromethcathinone (R), 4-methylethcathinone (R), amphetamine (R), methamphetamine (R), 
methylone (R), pentedrone (R), pentylone (R) 
63 
 
[EMIm][L-lactate]: 1-ethyl-3-methylimidazolium-L-lactate; [EMIm]Br: 1-ethyl-3-methylimidazolium-Br; DTAC: trimethyl ammonium chloride; L-AlaC4NTf2: L-alanine tert butyl 







Table 4.- LODs obtained for different drugs in chiral CE with different detection systems and preconcentration techniques. 
CD Drug (LOD μg/mL) Detection Precon. Tech. Ref. 
S-β-CD ofloxacin (0.46), ornidazole (0.54) UV-vis (230 nm)  15 
HP-γ-CD iodiconazole (4.6) UV-vis (200 nm)  33 
CM-β-CD meptazinol (2.5) UV-vis (237 nm)  24 
RAMEB sotalol (1.13) UV-vis (232 nm)  31 
RAMEB amlodipine (2.31) UV-vis (238 nm)  27 
β-CD carvedilol (1.13) UV-vis (242 nm)  28 
M-β-CD sibutramine (0.25) UV-vis (225 nm)  75 
SBE-β-CD isradipine (2.16) UV-vis (239 nm)  32 
CM-β-CD zopiclone (0.01) UV-vis (200 nm)  80 
SBE-β-CD chloroquine (0.6) UV-vis (225 nm)  81 
S-β-CD cetirizine (0.075) UV-vis (195 nm)  35 
S-α-CD ornidazole (0.3) UV-vis (277 nm)  21 
P-γ-CD tolterodine (0.33) UV-vis (200 nm)  23 
CM-β-CD amlodipine (1.0) UV-vis (237 nm)  39 
A-β-CD valsartan (0.1) UV-vis   34 
HP-β-CD+[EMIm][L-lactate] ofloxacin (0.53) UV-vis   57 
β-CD + [EMIm][L-lactate] zopiclone (0.3) UV-vis   58 
S-α-CD bupropion (0.048) phosphorescence  84 
SBE-β-CD bupivacaine (0.052) conductivity  20 
CM-β-CD anisodamine (0.18), atenolol (0.15), metoprolol (0.08) ECL  69 
Succ-γ-CD carnitine (0.01) IT-MS  85 
HS-γ-CD 4-fluoromethcathinone (1.2x10-3), dimethylcathinone (0.011), ethcathinone 
(1.0x10-3), buphedrone (3.5x10-3), pentedrone (3.7x10-3), methedrone (5.0x10-3), 
methylone (9.5x10-3), mephedrone (5.0x10-3), ethylone (3.8x10-3), 1-(3,4-
dimethylphenyl)-2-(methylamino)propan-1-one (5.0x10-3), Pentylone (6.7x10-3), 
1-(Benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (5.5x10-3) 




HP-β-CD duloxetine (0.02), duloxetine (0.2) IT-MS  86 
α-CD trimipramine (7x10-3) UV-vis (214 nm) EME 36 
HP-β-CD amlodipine (3x10-3) UV-vis (214 nm) EME 87 
HP-β-CD propranolol (7x10-3) UV-vis (214 nm) EME 37 
β-CD methamphetamine (0.2x10-3), methylenedioxymethamphetamine (0.08x10-3), 
ketamine (0.15x10-3) 
UV-vis (200 nm) DLLME 88 
S-β-CD cetirizine (0.037), hydroxyzine (0.075) UV-vis (214 nm) DLLME 22 
CM-β-CD zopiclone (0.27x10-3), desmethylzopiclone (0.15x10-3) UV-vis (310 nm) DLLME 25 
CM-β-CD carvedilol (4x10-3) UV-vis (241 nm) DLLME + FASI 40 
DM-β-CD + TM-β-CD pindolol (2.5x10-5), oxprenolol (1.1x10-4), propranolol (2.6x10-5) UV-vis (220 nm) FASI 55 
HS-γ-CD norketamine (0.18) UV-vis (195 nm)  92 
S-β-CD ketamine (0.02), norketamine (0.02) UV-vis (200 nm)  93 
S-β-CD ketamine (8x10-3), norketamine (8x10-3) UV-vis (195 nm)  94 
 
 
